Healthcare News

New Taipei City, Taiwan/San Francisco, CA, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to...

HONG KONG, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the "Company"), a leading provider of over-the-counter (“OTC”) pharmaceutical cross-border e-commerce...

Dr. Falk Pharma and Renexxion move closer to finalizing the naronapride global Phase 3 program in gastroparesis, with alignment reached with FDA and EMA

Fenebrutinib FENtrepid and FENhance 1 & 2 late-breaking data demonstrate a therapeutic effect on chronic active lesions, addressing a primary driver of long-term disability progression in multiple...

Cerenome reports preclinical data suggesting REYOBIQ damages tumor DNA and activates immunity, with enhanced activity when combined with anti-PD-1.

Miv-cel reversed disability and achieved durable efficacy across all primary and secondary endpoints through one year, with nearly all patients remaining off chronic immunotherapies  Deep B-cell...

Final pre-MAA package submitted to MHRA on October 20, 2026Full MAA submission targeted for early February 2027, under a revised strategy that could bring potential UK approval forward by...

VMS063 is a novel, potential first- and best-in-class monoclonal antibody investigational candidate discovered by Invivyd VMS063 demonstrated potent in vitro antiviral activity against contemporary...

EVERGREEN Phase 3 Trial-in-Progress poster presents planned study design of JADE101 in IgA nephropathy; initiation now expected in the fourth quarter of 2026JUNIPER Phase 2 Trial-in-Progress poster...

Elion will present new turletricin clinical data at IDWeek 2026, including three Phase 1 studies and a Phase 2 cryptococcal meningitis study.